盘前市场动向 市场消息 多家科技巨头财报本周亮剑：AI万亿豪赌迎生死大考。微软、Meta Platforms和特斯拉将于周三公布财报，苹果紧随其后于周 四公布。随着大型科技公司准备在未来几周陆续公布季度财报，AI交易正走向一个关键节点。"美股七巨头"此前被视为市场中 毫无争议的赢家，但这一叙事在今年以来已明显动摇，投资者开始追逐周期股、小盘股以及国际市场的动量。本轮财报季将考 验这些超大市值科技股的韧性，尤其是在市场从少数赢家向更广泛标的扩散的背景下。此外，在存储芯片行业已进入"超级周 期"之际，韩国两大存储芯片巨头——SK海力士和三星电子——本周将公布财报。华尔街分析师们对存储芯片/存储产品相关核 心公司的基本面与股价前景正在变得愈发积极。 鲍威尔能否"硬刚"到底?市场已经押注美联储"不屈服"。今年以来，关于美联储独立性的博弈已升级多个层级，但这家全球最 重要的央行几乎没有妥协的迹象——如今它还获得了最高法院与资深政客的支持。这种支持是否让美联储有底气强硬抵制"加 速降息"的压力，将成为本周的核心考验。本周的联邦公开市场委员会(FOMC)会议几乎肯定不会开启加速宽松周期。但鲍威尔 如何规划未来的政策路径、如 ...

Group 1 - The core viewpoint of the article highlights that 23 group standards in areas such as photovoltaic modules and fine ceramics have been recognized as international standard proposals, reflecting China's commitment to high-quality development in standardization [1] - The State Administration for Market Regulation is actively promoting the transformation of advanced group standards into international standards, achieving positive progress in this initiative [1] - Various social organizations, including the China Photovoltaic Industry Association and the Zhongguancun Materials Testing Technology Alliance, are collaborating with leading enterprises, research institutions, and universities to leverage China's technological advantages in relevant fields [1] Group 2 - The article mentions that the 23 group standards cover advanced fields such as photovoltaic modules, fine ceramics, and biotechnology, which have been recognized by the International Organization for Standardization and the International Electrotechnical Commission [1] - The State Administration for Market Regulation plans to encourage the formulation of group standards based on innovative technologies in emerging industries like new energy, new materials, aerospace, and low-altitude economy, contributing to the international standardization efforts [1]

| RVMD Revolution Medicines | | | | --- | --- | --- | | 117.630 ↓ -1.180 -0.99% | | 收盘价 01/23 16:00 美东 | | 90.580 ↓ -27.050 -23.00% | | 盘前价 01/26 04:08 美东 | | 三 四 四 图 图 图 中 白选 | | ● 快捷交易 | | 最高价 120.630 | 开盘价 118.400 | 成交量 252.24万 | | 最低价 117.590 | 昨收价 118.810 | 成交额 3亿 | | 平均价 118.797 | 市盈率ITM 亏损 | 总市值 227.4亿(…) | | 振 幅 2.56% | 市盈率(静) 亏损 | 总股本 1.93亿 | | 换手率 1.45% | 市净率 14.240 | 流通值 204.63亿 | | 52周最高 124.490 | 委 比 -99.56% | 流通股 1.74亿 | | 52周最低 29.170 | 量 比 0.63 | 包 主 1股 | | 历史最高 124.490 | 股息TIM -- | | | 历史最低 ...

Core Viewpoint - The Chinese government is focusing on enhancing service consumption and promoting high-quality development in various sectors, including culture, tourism, and healthcare, as part of its 2025 business strategy [1][3][44]. Group 1: Consumption and Economic Growth - In 2025, China's total retail sales of consumer goods reached 50.1 trillion yuan, marking a 3.7% increase, with consumption contributing 52% to economic growth, up by 5 percentage points [3][14]. - The implementation of the "old for new" policy boosted sales of durable goods, with sales in related categories like automobiles and home appliances reaching 2.61 trillion yuan, benefiting 366 million people [3][14]. - Service retail sales grew by 5.5%, with sectors like cultural and recreational services, tourism, and transportation seeing double-digit growth [3][14][44]. Group 2: Foreign Trade and Investment - In 2025, China's total goods imports and exports reached 45.47 trillion yuan, a 3.8% increase, while service trade grew by 7.1% [4][5]. - The number of enterprises engaged in foreign trade exceeded 780,000, with private enterprises accounting for 57.3% of total foreign trade [4][5]. - Foreign direct investment saw a 19.1% increase, with over 70,000 new foreign enterprises established, and high-tech industries accounted for 32.3% of total foreign investment [5][6]. Group 3: Bilateral and Multilateral Cooperation - China signed 24 free trade agreements with 31 countries and regions, covering 45% of its total goods trade [6][9]. - The government is actively participating in multilateral trade discussions and has proposed reforms to the World Trade Organization to enhance global trade stability [27][28]. - The "Belt and Road" initiative has led to a 6.3% increase in trade with partner countries, reaching 23.6 trillion yuan in 2025 [9][10]. Group 4: Future Strategies - The government plans to continue promoting service consumption by optimizing supply and removing unreasonable restrictions in the service sector [44][46]. - There will be a focus on enhancing the quality of service consumption, including expanding the service industry and encouraging fair competition [44][46]. - The strategy includes fostering new growth points in service consumption, such as transportation, home services, and digital services, to meet evolving consumer demands [46].

市场监管总局将根据"十五五"规划建议，在新能源、新材料、航空航天、低空经济等新兴产业领域，鼓 励基于创新技术制定团体标准，推动产业应用，为国际标准储备先进技术方案贡献中国力量。 （文章来源：央视新闻） 记者今天了解到，2025年市场监管总局持续推动团体标准高质量发展，指导将先进团体标准转化为国际 标准，取得积极进展。 中国光伏行业协会、中关村材料试验技术联盟、中国细胞生物学学会等社会团体，组织产业领军企业、 科研机构、高等院校等单位，充分发挥我国在相关技术领域的领先优势，制定并组织实施一批先进的团 体标准，其中光伏组件、精细陶瓷、生物技术等领域的23项团体标准已经被国际标准化组织、国际电工 委员会确认为国际标准提案，正在按程序制定成为国际标准。 ...

默沙东正寻找能增强其治疗产品组合的交易，以应对专利到期带来的损失，预计未来五年内专利到期将 导致其销售额减少180亿美元。Revolution目前有多种化合物正在研发中，其一种用于治疗转移性胰腺癌 的主导药物的关键性研究结果，预计于今年夏季公布。 美股频道更多独家策划、专家专栏，免费查阅>> 1月26日，据华尔街日报，默沙东据报已终止收购生物技术公司Revolution Medicines的谈判，原因是双 方未能就价格达成协议。消息人士指，这笔交易对Revolution的估值可能约为300亿美元，并补充称谈判 可能会重启，或可能会出现其他竞购者。 责任编辑：栎树 ...

Group 1 - Merck (MRK.US) has halted acquisition talks with Revolution Medicines (RVMD.US) due to disagreements over the purchase price, which was estimated to value Revolution Medicines at around $30 billion [1] - Merck is seeking to strengthen its treatment portfolio to address an anticipated $18 billion loss in sales over the next five years due to patent expirations, particularly with its key cancer drug Keytruda losing patent protection by the end of this decade [1] - The potential acquisition of Revolution Medicines could provide Merck with access to its experimental drug Daraxonrasib, which is a key asset for the company [1][2] Group 2 - Revolution Medicines is developing Daraxonrasib, an oral targeted drug that acts as a multi-selective inhibitor of RAS, aimed at treating cancers driven by RAS gene mutations [2] - Daraxonrasib is currently being evaluated in four global Phase 3 clinical trials, including three studies focused on pancreatic ductal adenocarcinoma (PDAC) and one on locally advanced or metastatic RAS-mutant non-small cell lung cancer (NSCLC) [2] - The RASolute304 clinical trial, which assesses the safety and efficacy of Daraxonrasib in resectable PDAC patients, has enrolled its first patient and plans to include approximately 500 patients [3] Group 3 - The pancreatic cancer treatment market is projected to expand tenfold to over $3 billion by 2035, driven by Daraxonrasib [3] - Daraxonrasib has been selected by the FDA for a program aimed at accelerating the approval of promising drugs, with expectations for it to be approved by 2026 [3]

Core Insights - The CEO of Mubadala Group emphasizes the focus on artificial intelligence and robotics as key drivers of industrial growth and future investment guidance [1] - Mubadala has been expanding its technology investment portfolio, including sectors such as semiconductors, data centers, and AI infrastructure [1] - The intersection of AI and robotics and their impact on manufacturing and industry is a particular area of interest for Mubadala [1] - Life sciences, healthcare, and biotechnology are also prioritized investment areas for the fund [1]

Group 1 - The article emphasizes the transformative power of a new technological revolution reshaping the global industrial landscape amidst geopolitical fluctuations and supply chain restructuring [1] - It highlights the integration of capital, technology, and consumption as barriers dissolve, leading to cross-industry innovation opportunities in China [1] - The article discusses the Northeast revitalization strategy as a significant national regional strategy, leveraging its industrial foundation, natural resources, and unique geographical advantages to find new engines of growth [1] Group 2 - The 2026 Changbai Mountain Forum will focus on "Investment Empowerment and Cultural Tourism Symbiosis," aiming to gather insights and consensus on investment trends and industrial futures in the post-pandemic global economy [1] - The forum will feature prominent experts and entrepreneurs discussing key topics such as "AI Empowering New Productive Forces" and "Capital-Driven Brand Growth" [2] - A closed-door meeting led by economist Fu Peng will delve into the wealth secrets of the AI era, exploring how AI technology can reshape the industrial landscape and drive new productive forces [2]

Core Viewpoint - Sana Biotechnology (SANA) has shown a significant price increase of 10.4% over the past four weeks, with a mean price target of $8.71 indicating a potential upside of 74.2% from its current price of $5 [1]. Price Targets - The average price target consists of seven estimates ranging from a low of $6.00 to a high of $12.00, with a standard deviation of $2.43, suggesting a variability in analyst estimates [2]. - The lowest estimate indicates a 20% increase from the current price, while the highest suggests a 140% upside potential [2]. Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about SANA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 0.6% increase over the last 30 days [4][12]. - The Zacks Consensus Estimate for the current year has improved, with one estimate moving higher and no negative revisions [12]. - SANA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - While price targets are often sought after by investors, their reliability has been questioned, as they can mislead rather than guide investment decisions [3][7]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]. - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement, serving as a starting point for further research [9].